Vitrolife's CFO to leave

Vitrolife's CFO to leave

Anna Ahlberg, Vitrolife's CFO for just over 4 years, has decided to terminate
her employment at Vitrolife. Anna will begin to work at Global Health Partner,
as Head of the company's spine surgery business unit. 

”Anna has done a great job at Vitrolife, amongst other things by organizing and
structuring our finance activities so that they are at a recognized very high
level. We wish her the very best of luck in her new position,” says Magnus
Nilsson, CEO.

Anna Ahlberg will terminate her employment at Vitrolife in January 2009. The
work of recruiting her successor is ongoing.





September 19, 2008
Kungsbacka, Sweden 

Magnus Nilsson
CEO








Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

The information in this press release is such as that which Vitrolife is
required to publish in accordance with the Securities Exchange and Clearing
Operations Act. The information was submitted for publication on September 19,
2008 at 3.30 pm.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.